TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24665133

Group type: EXPERIMENTAL
Intervention: Sickle cell patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sickle cell patients during acute pain crisis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sickle cell patients recovered from pain crisis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 24665972

Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Continuous monitoring (CM) devices
Number of subjects: 647
Study: 24665992

Group type: EXPERIMENTAL
Intervention: Protecta XT dual-chamber ICD (n = 114)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Defibrillator with cardiac resynchronization therapy (n = 132)
Number of subjects: 246
Study: 24666542

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 84
Study: 24666686

Group type: EXPERIMENTAL
Intervention: Methadone 0.2 mg·kg(-1) per 8 h in neonates
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Infusion dosing
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Racemate of methadone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: EDDP and EMDP metabolites
Number of subjects: 56
Study: 24667011

Group type: EXPERIMENTAL
Intervention: Sequential application of four preventive measures
Number of subjects: 1935
Study: 24667717

Group type: EXPERIMENTAL
Intervention: vintafolide
Number of subjects: 49
Study: 24668327

Group type: EXPERIMENTAL
Intervention: Temsirolimus-based regimens
Number of subjects: 0
Study: 24668831

Group type: EXPERIMENTAL
Intervention: Cryocontact therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24668858

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg orally three times a week
Number of subjects: 7
Study: 24669961

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 international units/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24669960

Group type: EXPERIMENTAL
Intervention: IV rt-PA treatment
Number of subjects: 369
Study: 24669965

Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients
Number of subjects: 234

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 234
Study: 24670013

Group type: EXPERIMENTAL
Intervention: Helping Babies Breathe (HBB) training program
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: HBB/ENC training and quality monitoring and improvement package
Number of subjects: 30000
Study: 24670075

Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management (SWM) measure
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: SWM scores
Number of subjects: 640
Study: 24670085

Group type: EXPERIMENTAL
Intervention: Obese children with MetS
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: UFC
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: HOMA index
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: SC
Number of subjects: 264
Study: 24670165

Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378) at doses of 400 mg or more per day
Number of subjects: 130
Study: 24670428

Group type: EXPERIMENTAL
Intervention: SootherMask (SM) with Respimat Soft Mist Inhaler (SMI) and InspiraChamber (IC)
Number of subjects: 13
Study: 24670608

Group type: EXPERIMENTAL
Intervention: Temozolomide at 150 mg/m(2)/day on days 1-7 and days 15-21 during each 4-week cycle
Number of subjects: 60
Study: 24670710

Group type: EXPERIMENTAL
Intervention: Totally subcutaneous implantable defibrillator (S-ICD)
Number of subjects: 472
Study: 24670864

Group type: EXPERIMENTAL
Intervention: fenestrated and/or branched endovascular repair (f/b-EVAR)
Number of subjects: 268
Study: 24671104

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 6726

Group type: EXPERIMENTAL
Intervention: Change in BMI
Number of subjects: 6726
Study: 24671709

Group type: EXPERIMENTAL
Intervention: Low-choline diet
Number of subjects: 79
Study: 24671831

Group type: EXPERIMENTAL
Intervention: RP-1127 (glyburide for injection)
Number of subjects: 10
Study: 24671981

Group type: EXPERIMENTAL
Intervention: STONE score (0-13) - low probability (score 0-5)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: STONE score (0-13) - moderate probability (score 6-9)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: STONE score (0-13) - high probability (score 10-13)
Number of subjects: 1531
Study: 24674873

Group type: EXPERIMENTAL
Intervention: Bosutinib at 400 mg/day plus exemestane at 25 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bosutinib at 300 mg/day plus exemestane at 25 mg/day
Number of subjects: 42
Study: 24674874

Group type: EXPERIMENTAL
Intervention: Bosutinib (400 mg/day) plus Letrozole (2.5 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bosutinib plus Letrozole
Number of subjects: 16
Study: 24674961

Group type: EXPERIMENTAL
Intervention: Patients with OCD
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 24675204

Group type: EXPERIMENTAL
Intervention: Innervated flap
Number of subjects: 166

Group type: COMPARATOR
Intervention: Noninnervated flap
Number of subjects: 166

Group type: COMPARATOR
Intervention: Single-innervated flap
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Flaps harvested from the middle phalanx
Number of subjects: 166
Study: 24675585

Group type: EXPERIMENTAL
Intervention: TB LAM test
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Urine TB LAM test plus sputum smear microscopy
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Positive TB LAM test
Number of subjects: 1013
Study: 24675657

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tetraethylammonium
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bradykinin, Acetylcholine, Sodium Nitroprusside
Number of subjects: 160
Study: 24675918

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 4±2°C for 20 minutes
Number of subjects: 35
Study: 24676282

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 1260
Study: 24676783

Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD) patients
Number of subjects: 38
Study: 24677205

Group type: EXPERIMENTAL
Intervention: Therapist with disengaged feelings
Number of subjects: 2

Group type: COMPARATOR
Intervention: Therapist with engaged feelings
Number of subjects: 2
Study: 24678741

Group type: EXPERIMENTAL
Intervention: Tourniquet assisted TKA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-tourniquet assisted TKA
Number of subjects: 80
Study: 24678902

Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8 for 2 induction cycles.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 on day 1 and oral vinorelbine 20 mg on days 1, 3 and 5 during concomitant radiotherapy 2 Gy daily, 5 days/week for a total of 66 Gy.
Number of subjects: 70
Study: 24678911

Group type: EXPERIMENTAL
Intervention: Pac-IFicO programme
Number of subjects: 500
Study: 24679131

Group type: EXPERIMENTAL
Intervention: Pharmacist-led follow-up program
Number of subjects: 4
Study: 24679462

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (60 Gy of conventional irradiation to the surgical bed for 6 weeks)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 1005
Study: 24680929

Group type: EXPERIMENTAL
Intervention: Microaneurysm turnover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subclinical macular edema identified by OCT and mfERG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 0
Study: 24681017

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) using the Symplicity Flex™ catheter
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 59
Study: 24681609

Group type: EXPERIMENTAL
Intervention: lotrafilcon A silicone hydrogel lenses
Number of subjects: 205
Study: 24681911

Group type: EXPERIMENTAL
Intervention: Metabolically abnormal but normal weight (MANW)
Number of subjects: 1012
Study: 24681993

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine (TDF-FTC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine (ABC-3TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not carrying HLA-DQ3)
Number of subjects: 0
Study: 24682387

Group type: EXPERIMENTAL
Intervention: Empirical stroke risk assessed using CHADS2 score (≥2)
Number of subjects: 10094

Group type: EXPERIMENTAL
Intervention: Empirical bleeding risk assessed using ATRIA score (≥5)
Number of subjects: 10094

Group type: COMPARATOR
Intervention: Physician estimates of stroke risk
Number of subjects: 10094

Group type: COMPARATOR
Intervention: Physician estimates of bleeding risk
Number of subjects: 10094

Group type: EXPERIMENTAL
Intervention: Anticoagulation use among patients with high stroke risk
Number of subjects: 10094

Group type: COMPARATOR
Intervention: Impact of physician and empirical estimates of bleeding on treatment choice
Number of subjects: 10094
Study: 24682512

Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 85
Study: 24682613

Group type: EXPERIMENTAL
Intervention: Second consecutive LNG-IUS
Number of subjects: 204
Study: 24683529

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX) - resistance bands, 3 times weekly during chemotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 14
Study: 24684464

Group type: EXPERIMENTAL
Intervention: High-fat diet (3180 kJ/d) for 56 days
Number of subjects: 39
Study: 24684466

Group type: EXPERIMENTAL
Intervention: Teriparatide treatment for 18 months
Number of subjects: 20
Study: 24684783

Group type: EXPERIMENTAL
Intervention: Handheld echocardiography (HHE)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 190
Study: 24684785

Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg daily) and Carboplatin (AUC 6, later decreased to AUC 5 and AUC 4) every 3 weeks
Number of subjects: 25
Study: 24685375

Group type: EXPERIMENTAL
Intervention: Branched endograft treatment for arch aneurysms
Number of subjects: 38

Group type: COMPARATOR
Intervention: Branched endograft treatment for arch aneurysms (early experience group)
Number of subjects: 38
Study: 24685605

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) in regular medical care
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) in telemedicine-based coagulation service
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) in both cohorts
Number of subjects: 2500
Study: 24685661

Group type: EXPERIMENTAL
Intervention: Personality traits (neuroticism, conscientiousness)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cognitive restraint of eating
Number of subjects: 102
Study: 24686108

Group type: EXPERIMENTAL
Intervention: Exception from informed consent (EFIC) availability
Number of subjects: 191

Group type: COMPARATOR
Intervention: Minority status
Number of subjects: 191
Study: 24687068

Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm combining clinical decision score, d-dimer testing, and ultrasonography
Number of subjects: 406
Study: 24687156

Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stents with biodegradable polymer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-generation drug-eluting stents with durable polymer
Number of subjects: 0
Study: 24687408

Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine (250 mg/m²) in a 6-h infusion plus cisplatin (35 mg/m²) on days 1 and 8 every three weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine infusion plus cisplatin
Number of subjects: 39
Study: 24687837

Group type: EXPERIMENTAL
Intervention: MIPI low-risk group
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: MIPI intermediate-risk group
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: MIPI high-risk group
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: MIPI
Number of subjects: 958
Study: 24688075

Group type: EXPERIMENTAL
Intervention: Standard-titer Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age, with or without a second dose at 18 months of age
Number of subjects: 408
Study: 24689499

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 327
Study: 24690111

Group type: EXPERIMENTAL
Intervention: MDD outpatients
Number of subjects: 95

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 95
Study: 24691204

Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: T-cell activation
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Systemic inflammation
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: sCD14, hs-CRP, fibrinogen
Number of subjects: 147
Study: 24691436

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (110 mg bid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 100
Study: 24692527

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4102
Study: 24692579

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m(2) as a 3-h i.v. infusion every 3 weeks until progression or intolerance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 40
Study: 24692582

Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography (CTA) screening
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 52
Study: 24693532

Group type: EXPERIMENTAL
Intervention: Mag-paDRE program
Number of subjects: 925
Study: 24694729

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 697
Study: 24695685

Group type: EXPERIMENTAL
Intervention: Ipilimumab administration
Number of subjects: 20
Study: 24695882

Group type: EXPERIMENTAL
Intervention: Pertubation of the uterine cavity prior to insemination in 79 patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no pertubation)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study: 24696183

Group type: EXPERIMENTAL
Intervention: [(18) F]VM4-037
Number of subjects: 4
Study: 24697160

Group type: EXPERIMENTAL
Intervention: Multifaceted retention strategies including community engagement, interpersonal relationship building, reduction of external barriers, staff capacity building, and external tracing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no specific intervention mentioned).
Number of subjects: 0
Study: 24697851

Group type: EXPERIMENTAL
Intervention: Rifaximin (275, 550, and 1100 mg twice daily for 2 weeks; 550 mg twice daily for 4 weeks; 550 mg three times daily for 2 weeks)
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 1932
Study: 24698176

Group type: EXPERIMENTAL
Intervention: RH-PAT score in adolescents with overweight or obesity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Baseline pulse amplitude in adolescents with overweight or obesity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of baseline pulse amplitude
Number of subjects: 27

Group type: COMPARATOR
Intervention: RH-PAT score in healthy controls
Number of subjects: 27

Group type: COMPARATOR
Intervention: Baseline pulse amplitude in healthy controls
Number of subjects: 27
Study: 24699276

Group type: EXPERIMENTAL
Intervention: Progressive knee-extension strength training (ankle weight cuffs, 3 sets of 10 repetitions)
Number of subjects: 36
Study: 24699307

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 64
Study: 24699379

Group type: EXPERIMENTAL
Intervention: Diffuse-trickling GA
Number of subjects: 61
Study: 24699462

Group type: EXPERIMENTAL
Intervention: Participants with target organ damage (TOD)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Measurement of peripheral and central blood pressure
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Size of eye fundus arteries and veins
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Oxidative stress
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Polymorphisms in VAV-2 and VAV-3 genes
Number of subjects: 486

Group type: COMPARATOR
Intervention: Participants without target organ damage (TOD)
Number of subjects: 486
Study: 24699474

Group type: EXPERIMENTAL
Intervention: ART (antiretroviral therapy)
Number of subjects: 143
Study: 24699910

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² IV on days 1 and 8 of each 3-week cycle
Number of subjects: 56
Study: 24700623

Group type: EXPERIMENTAL
Intervention: Clinician-rated assessment
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Self-report assessment
Number of subjects: 644
Study: 24703206

Group type: COMPARATOR
Intervention: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses of 50mg, 200mg, and 10mg/day respectively.
Number of subjects: 3759

Group type: COMPARATOR
Intervention: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses.
Number of subjects: 3759
Study: 24703920

Group type: EXPERIMENTAL
Intervention: HF with an ICD with appropriate intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: HF with an ICD without appropriate intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating SCN5A variant levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating SCN5A variants
Number of subjects: 0
Study: 24704179

Group type: EXPERIMENTAL
Intervention: Use of mobile devices and SMS for diet and exercise information
Number of subjects: 12
Study: 24704719

Group type: EXPERIMENTAL
Intervention: telaprevir
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: boceprevir
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: telaprevir or boceprevir
Number of subjects: 511
Study: 24704773

Group type: COMPARATOR
Intervention: Asunaprevir 200 mg twice daily in mild hepatic impairment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Asunaprevir 200 mg twice daily in moderate hepatic impairment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Asunaprevir 200 mg twice daily in severe hepatic impairment
Number of subjects: 34
Study: 24704921

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients recovering from IE
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Support from relatives and healthcare professionals
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physical, cognitive, and emotional experiences post-IE
Number of subjects: 11
Study: 24705186

Group type: EXPERIMENTAL
Intervention: Radotinib 400 mg twice daily for 12 cycles
Number of subjects: 77
Study: 24705452

Group type: EXPERIMENTAL
Intervention: EIAV-CMV-MYO7A (UshStat)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: EIAV-CMV-GFP/MYO7A vectors
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: UshStat
Number of subjects: 1

Group type: COMPARATOR
Intervention: EIAV-CMV-Null (control)
Number of subjects: 1

Group type: COMPARATOR
Intervention: EIAV-CMV-GFP
Number of subjects: 1

Group type: COMPARATOR
Intervention: EIAV-RK-GFP (photoreceptor specific)
Number of subjects: 1
Study: 24705492

Group type: EXPERIMENTAL
Intervention: First-line combined fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 237
Study: 24705867

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Stimulant
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Combination of both treatments
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Parent-rated GIPD
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Physician-rated GIPD
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Patient-rated GIPD
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Parent-rated EESC
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Patient-rated EESC
Number of subjects: 504
Study: 24705975

Group type: EXPERIMENTAL
Intervention: Pazopanib (400 or 600 mg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg) on Day 15 with bevacizumab (7.5 mg/kg iv)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg) on Day 16 (24h after bevacizumab)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg)
Number of subjects: 25
Study: 24707402

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (lansoprazole 30 mg twice daily, amoxicillin 0.75 g twice daily, clarithromycin 250 mg twice daily for 14 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: H. pylori stool antigen test positive patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Baseline proteinuria levels
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 24708624

Group type: EXPERIMENTAL
Intervention: HLA-A*2402-restricted multi-peptide vaccine combined with CRT (radiotherapy 60 Gy, cisplatin 40 mg/m², 5-fluorouracil 400 mg/m²)
Number of subjects: 11
Study: 24708667

Group type: EXPERIMENTAL
Intervention: Alpha fetoprotein DNA prime and adenovirus boost vaccination (3 plasmid DNA injections followed by 1 AdV injection, all intramuscularly)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Alpha fetoprotein DNA prime and adenovirus boost vaccination
Number of subjects: 2
Study: 24708677

Group type: EXPERIMENTAL
Intervention: Internet-based counseling program based on the 'patient journey' model
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 80